- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04514965
Bezafibrate in Patients With Primary Biliary Cholangitis (PBC)
Measuring Macrophage Activation Markers and Influence on Bile Acid Composition in Patients With Primary Biliary Cholangitis After Treatment With Bezafibrate
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary biliary cholangitis (PBC) is an autoimmune cholestatic liver disease characterized by destruction of intrahepatic bile ducts and progression to liver fibrosis and cirrhosis. The diagnosis of PBC is based on the presence of two of three major criteria; unexplained serum alkaline phosphatase (ALP) >1.5 times upper normal limit for more than 24 weeks, presence of anti-mitochondrial antibodies (AMA), and compatible liver histology.
Ursodeoxycholic acid (UDCA) is currently the only approved drug used to treat PBC and patients treated with UDCA have improved survival. In Denmark all PBC patients are offered UDCA treatment. However, up to 40% of PBC patients may be classified as insufficient responders to UDCA treatment with male gender, low age, and low Vitamin D level at diagnosis associated with insufficient response. More precise predictors of insufficient response to UDCA treatment are important to find as insufficient responders have worse 10-year survival probability than responders. The high proportion of insufficient responders has fuelled the search for novel treatment options, including fibrates, budesonide, and obeticholic acid. Despite response to UDCA treatment, liver transplantation remains the only cure for PBC and patients with expected survival less than one year are potential candidates for liver transplantation.
Bezafibrate Bezafibrate is a pan-peroxisome proliferator-activated receptor (PPAR) agonist. For decades, bezafibrate has been prescribed for various indications including hyperlipidemia. Thus, adverse effects are well described. Recently, a phase 3 trial showed promising results as an add-on therapy to UDCA in reducing ALP in PBC patients, who had insufficient response to UDCA alone. Hence, Danish hepatologists are starting to use bezafibrate as second line, add-on, therapy in PBC patients.
Soluble CD163 and fibrosis markers In PBC, inflammation is attributed to an immune response to mitochondrial autoantigens followed by development of anti-mitochondrial antibodies (AMAs); and accompanied by inflammation of small bile ducts. The pathogenesis includes both CD4 and CD8 cells, which in the presence of biliary cells expressing the 2-oxo-dehydrogenase pathway (PDC-E2) activates macrophages via granulocyte macrophage colony-stimulating factor. The activated macrophages, together with AMAs, produce a proinflammatory response with subsequent liver inflammation and fibrosis. Thus, macrophages seem to be involved in PBC disease severity and progression. The investigators recently showed that the macrophage activation marker soluble (s)CD163 is associated with long-term prognosis in PBC patients. Further, the investigators research group have shown increased levels of sCD163 in relation to liver fibrosis/cirrhosis in patients with chronic viral hepatitis (HBV and HCV), non-alcoholic fatty liver disease (NAFLD/NASH) and alcoholic liver disease (alcoholic hepatitis and cirrhosis) and liver disease severity including risk of portal hypertension and development of complications and mortality. Moreover, the investigators also demonstrated sCD163 is associated with early and long-term prognosis of patients with cirrhosis and acute-on-chronic liver failure.
Fibrosis is a hallmark of liver disease progression and extracellular matrix (ECM) turnover is a prominent feature of chronic inflammatory liver diseases including PBC. ECM protein degradation and formation generate fragments reflecting aspects of the tissue turnover balance when quantified in the blood. PRO-C3 and PRO-C4 reflect type III and IV collagen formation, whereas C3M and C4M are markers for degradation of type III and IV. The investigators aim to investigate changes in these fibrosis markers before and after bezafibrate treatment, to demonstrate if these novel finger print protein biomarkers may be useful for treatment response in PBC patients.
Bile acids In PBC there is intrahepatic accumulation of potentially cytotoxic bile acids resulting in liver damage. Further the composition of bile acids is changed, resulting in changes of microbiota and in the integrity of the intestinal wall, potentially allowing an increased flux of inflammatory metabolites to the liver. Exploration of potential changes in bile acid profile caused by bezafibrate treatment may improve understanding of the treatment effects and provide identification of specific treatment targets.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Lars Bossen, MD
- Phone Number: +45 22800676
- Email: larsbossen@clin.au.dk
Study Contact Backup
- Name: Henning Grønbæk, Prof, MD
- Phone Number: +45 21679281
- Email: henngroe@rm.dk
Study Locations
-
-
-
Hvidovre, Denmark, 2650
- Recruiting
- Department of Medicine, Gastrounit Medical division
-
Contact:
- Henriette Ytting, MD, PhD
- Email: henriette.lambert@regionh.dk
-
Sub-Investigator:
- Line Molzen, MD
-
-
Region Midtjylland
-
Aarhus N, Region Midtjylland, Denmark, 8200
- Recruiting
- Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark
-
Principal Investigator:
- Henning Grønbæk, Prof, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- PBC patient offered bezafibrate treatment
Exclusion Criteria:
- patient age under 18
- life expectancy less than 6 months
- known cancer
- planned liver transplantation within 6 months
- other liver disease (viral, autoimmune, alcohol, NAFLD/NASH)
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
PBC patients offered bezafibrate treatment
All patients started on bezafibrate treatment are offered inclusion in the study. First visit is before start of treatment. Afterwards patients will be seen at 4 weeks, 6 months, 1 year, 2 years and 3 years after inclusion. At all visits blood samples will be taken and liver stiffness will be measured using FibroScan. Further, they will be asked about pruritus. |
Blood sampling
Measurement of liver stiffness
Question about pruritus
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment effect on sCD163 levels
Time Frame: 4 weeks to 3 years
|
Treatment effect on sCD163 levels measured in mg/L
|
4 weeks to 3 years
|
Treatment effect on levels of fibrosis markers
Time Frame: 4 weeks to 3 years
|
Treatment effect on levels of fibrosis markers
|
4 weeks to 3 years
|
Treatment effect on liver stiffness
Time Frame: 4 weeks to 3 years
|
Treatment effect on liver stiffness measured in kilopascal
|
4 weeks to 3 years
|
Treatment effect on bile acid composition
Time Frame: 4 weeks to 3 years
|
investigation of bile acid composition before and after treatment
|
4 weeks to 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment effect on the degree of pruritus
Time Frame: 4 weeks to 3 years
|
Treatment effect on the degree of pruritus measured using questionaires
|
4 weeks to 3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Henning Grønbæk, Prof, MD, Aarhus University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PBC Beza AU
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Biliary Cirrhosis
-
University Health Network, TorontoUnknown
-
CymaBay Therapeutics, Inc.TerminatedPrimary Biliary Cirrhosis (PBC)Germany, United States, Canada, United Kingdom, Poland
-
Xijing Hospital of Digestive DiseasesUnknownPrimary Biliary CirrhosisChina
-
CymaBay Therapeutics, Inc.RecruitingPrimary Biliary CirrhosisUnited States, Korea, Republic of, Belgium, Spain, France, Switzerland, Romania, United Kingdom, Austria, Israel, Australia, Argentina, Canada, Chile, Germany, Greece, Hungary, Italy, Mexico, Netherlands, Poland, Czechia, New Zealand, Turke... and more
-
Target PharmaSolutions, Inc.Active, not recruitingBiliary Cirrhosis, PrimaryUnited States
-
IpsenActive, not recruitingPrimary Biliary CirrhosisUnited States, France, Spain, Belgium, Germany, Switzerland, Brazil, United Kingdom, Argentina, Canada, Chile, Italy, South Africa, Turkey
-
Instituto Mexicano del Seguro SocialActive, not recruitingPrimary Biliary CirrhosisMexico
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingPrimary Biliary CirrhosisChina
-
Zydus Therapeutics Inc.CompletedPrimary Biliary CirrhosisUnited States
-
CymaBay Therapeutics, Inc.CompletedPrimary Biliary CirrhosisUnited States, Germany, United Kingdom, Canada
Clinical Trials on Blood sampling
-
Medical University of GrazJoanneum Research Forschungsgesellschaft mbHCompleted
-
CardioRenalCompletedPotassium MeasurementBelgium
-
Centre Hospitalier Universitaire DijonCompletedPatients With Intellectual Disabilities Without an Obvious Clinical Diagnosis | Patients With Normal Array CGH and Previous Negative Genetic Investigations (WES-solo or WES-trio)France
-
Assistance Publique - Hôpitaux de ParisUnknownSepsis | Acute Circulatory FailureFrance
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Rennes University HospitalCompletedMultiple SclerosisFrance
-
Institut PasteurSanofi Pasteur, a Sanofi Company; Institut Pasteur of Cote d'IvoireCompletedBordetella Pertussis, Whooping CoughCôte D'Ivoire
-
University Hospital, ToulouseCompletedPneumonia, PneumocystisFrance
-
Royal Surrey County Hospital NHS Foundation TrustCompletedThyroid Carcinoma | Thyroid Cancer | Cancer of the Thyroid | Cancer of ThyroidUnited Kingdom
-
Institut CurieRecruitingProstate Cancer | Healthy DonorsFrance